TY - JOUR
T1 - A randomized controlled trial to isolate the effects of fasting and energy restriction on weight loss and metabolic health in lean adults
AU - Templeman, Iain
AU - Smith, Harry Alex
AU - Chowdhury, Enhad
AU - Chen, Yung Chih
AU - Carroll, Harriet
AU - Johnson-Bonson, Drusus
AU - Hengist, Aaron
AU - Smith, Rowan
AU - Creighton, Jade
AU - Clayton, David
AU - Varley, Ian
AU - Karagounis, Leonidas Georgios
AU - Wilhelmsen, Andrew
AU - Tsintzas, Kostas
AU - Reeves, Sue
AU - Walhin, Jean Philippe
AU - Gonzalez, Javier Thomas
AU - Thompson, Dylan
AU - Betts, James Alexander
N1 - Publisher Copyright:
© 2021 American Association for the Advancement of Science. All rights reserved.
PY - 2021/6/16
Y1 - 2021/6/16
N2 - Intermittent fasting may impart metabolic benefits independent of energy balance by initiating fasting-mediated mechanisms. This randomized controlled trial examined 24-hour fasting with 150% energy intake on alternate days for 3 weeks in lean, healthy individuals (0:150; n = 12). Control groups involved a matched degree of energy restriction applied continuously without fasting (75% energy intake daily; 75:75; n = 12) or a matched pattern of fasting without net energy restriction (200% energy intake on alternate days; 0:200; n = 12). Primary outcomes were body composition, components of energy balance, and postprandial metabolism. Daily energy restriction (75:75) reduced body mass (-1.91 } 0.99 kilograms) almost entirely due to fat loss (-1.75 } 0.79 kilograms). Restricting energy intake via fasting (0:150) also decreased body mass (-1.60 } 1.06 kilograms; P = 0.46 versus 75:75) but with attenuated reductions in body fat (-0.74 } 1.32 kilograms; P = 0.01 versus 75:75), whereas fasting without energy restriction (0:200) did not significantly reduce either body mass (-0.52 } 1.09 kilograms; P ≤ 0.04 versus 75:75 and 0:150) or fat mass (-0.12 } 0.68 kilograms; P ≤ 0.05 versus 75:75 and 0:150). Postprandial indices of cardiometabolic health and gut hormones, along with the expression of key genes in subcutaneous adipose tissue, were not statistically different between groups (P >0.05). Alternate-day fasting less effectively reduces body fat mass than a matched degree of daily energy restriction and without evidence of fasting-specific effects on metabolic regulation or cardiovascular health.
AB - Intermittent fasting may impart metabolic benefits independent of energy balance by initiating fasting-mediated mechanisms. This randomized controlled trial examined 24-hour fasting with 150% energy intake on alternate days for 3 weeks in lean, healthy individuals (0:150; n = 12). Control groups involved a matched degree of energy restriction applied continuously without fasting (75% energy intake daily; 75:75; n = 12) or a matched pattern of fasting without net energy restriction (200% energy intake on alternate days; 0:200; n = 12). Primary outcomes were body composition, components of energy balance, and postprandial metabolism. Daily energy restriction (75:75) reduced body mass (-1.91 } 0.99 kilograms) almost entirely due to fat loss (-1.75 } 0.79 kilograms). Restricting energy intake via fasting (0:150) also decreased body mass (-1.60 } 1.06 kilograms; P = 0.46 versus 75:75) but with attenuated reductions in body fat (-0.74 } 1.32 kilograms; P = 0.01 versus 75:75), whereas fasting without energy restriction (0:200) did not significantly reduce either body mass (-0.52 } 1.09 kilograms; P ≤ 0.04 versus 75:75 and 0:150) or fat mass (-0.12 } 0.68 kilograms; P ≤ 0.05 versus 75:75 and 0:150). Postprandial indices of cardiometabolic health and gut hormones, along with the expression of key genes in subcutaneous adipose tissue, were not statistically different between groups (P >0.05). Alternate-day fasting less effectively reduces body fat mass than a matched degree of daily energy restriction and without evidence of fasting-specific effects on metabolic regulation or cardiovascular health.
UR - http://www.scopus.com/inward/record.url?scp=85108346791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108346791&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.abd8034
DO - 10.1126/scitranslmed.abd8034
M3 - Article
C2 - 34135111
AN - SCOPUS:85108346791
SN - 1946-6234
VL - 13
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 598
M1 - eabd8034
ER -